Abstract: The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25° C. and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.

Abstract: The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25° C. and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.

Abstract: Disclosed are a phosphate-binding polymer having a true specific gravity of 1.18-1.24, tablets that solely consist of the particles of a phosphate-binding polymer having an average particle size of no more than 400 ?m, with at least 90% being occupied by particles no larger than 500 ?m, and having a true specific gravity of 1.18-1.24 and a water content of 1-14%, or tablets that contain both the particles and crystalline cellulose and/or low substituted hydroxypropyl cellulose, and a process for producing such tablets. The phosphate-binding polymer can be formulated as tablets either alone or in combination with specified additives. Whichever the case, the tablets have satisfactory hardness, contain the active ingredient in high proportion, have high phosphate-binding capability and exhibit rapid disintegrability in an acidic to neutral region while having little sensitivity to the strength of agitation.

Abstract: A quinolinone derivative pharmaceutical composition comprising a quinolinone derivative represented by the structural formula (I): wherein the quinolinone derivative is in the form of particles, which have an average particle diameter of 0.5 to 10 ?m and such a particle size distribution that particles having a particle diameter of 15 ?m or less account for 90% or more of the totality of the particles, and also have a fusion enthalpy of 30 J/g or more, and the surface of the particles are coated with a water-soluble composition containing a water-soluble polymer, can quickly dissolve an active ingredient in the digestive tract and is also superior in long-term storage stability.

Abstract: A tablet containing a phosphate-binding polymer, which has an average particle size of 400 &mgr;m or less, contains particles of 500 &mgr;m or less in particle size at a ratio of 90% or more and has a moisture content of 1 to 14%, together with crystalline cellulose and/or low substituted hydroxypropylcellulose and contains the active component at a high ratio, is excellent in the ability to bind to phosphate, and quickly disintegrates in an acidic to a neutral region.

Abstract: A quinolinone derivative pharmaceutical composition comprising a quinolinone derivative represented by the structural formula (I): 1

Abstract: A tablet containing a phosphate-binding polymer, which has an average particle size of 400 &mgr;m or less, contains particles of 500 &mgr;m or less in particle size at a ratio of 90% or more and has a moisture content of 1 to 14%, together with crystalline cellulose and/or low substituted hydroxypropyl cellulose and contains the active component at a high ratio, is excellent in the ability to bind to phosphate, and quickly disintegrates in an acidic to a neutral region.

Abstract: A tablet containing a phosphate-binding polymer, which has an average particle size of 400 &mgr;m or less, contains particles of 500 &mgr;m or less in particle size at a ratio of 90% or more and has a moisture content of 1 to 14%, together with crystalline cellulose and/or low substituted hydroxypropylcellulose, and a process for producing the same are disclosed. The phosphate-binding polymer tablet according to the present invention contains the active component at a high ratio, is excellent in the ability to bind to phosphate and is a quickly disintegrated in an acidic to a neutral region while being little affected by the stirring strength. Accordingly, it is an excellent preparation capable of regulating changes in bioavailability due to the gastrointestinal motions and pH value.

Abstract: A nuclear reactor facility including a primary containment vessel, a reactor pressure vessel installed in the primary containment vessel and accommodating a reactor core in a lower part thereof, and a vertical cylindrical wall disposed in a lower part of the primary containment vessel around and spaced from the reactor pressure vessel so as to delimit an annular space therebetween. The vertical cylindrical wall has an upper end disposed at a position higher than an upper end of the reactor core and a diaphragm extends substantially horizontally between the upper end of the vertical cylindrical wall and an inner wall of the primary containment vessel for cooperating with the vertical cylindrical wall to separate a space in the primary containment vessel around the reactor pressure vessel into a pressure suppression chamber and a drywell which includes annular space.

Abstract: A container-outer-periphery pool in which water is stored is provided between a primary containment vessel and a reactor building, and outside of a pressure suppression pool. Consequently, the natural heat transfer capabilities of reactor facilities is enhanced, and the inherent safety of the reactor facilities is improved.